Senhwa Biosciences Inc AI Stock Analysis
Senhwa Biosciences Inc (6492) AI Stock Analysis
Senhwa Biosciences Inc
(TPEx:6492)
The score is held down primarily by weak fundamentals: negligible revenue, a NT$265 million net loss, and roughly NT$248 million of annual cash burn, with shareholders' equity down nearly 70% since 2020 and a probable dilutive capital raise within a few years. A debt-free balance sheet and consistently narrowing losses and cash burn provide some offset. Technicals reinforce the caution, with the price below all major moving averages and negative MACD, though momentum readings are deeply oversold. Valuation offers no support, with negative earnings and no dividend. This is a high-risk, binary-outcome biotech whose value rests on future clinical and partnership milestones rather than current financial performance.
Senhwa Biosciences Inc (6492) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.44B
- Dividend Yield
- ―
- Average Volume (3M)
- 237.27K
- Price to Earnings (P/E)
- -9.1
- Beta (1Y)
- 0.52
- Revenue Growth
- 5.00%
- EPS Growth
- -6.49%
- Country
- TW
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Senhwa Biosciences Inc Business Overview & Revenue Model
Company Description
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its...
Senhwa Biosciences Inc Financial Statement Overview
Summary
Senhwa is a pre-commercial clinical-stage biotech with essentially no revenue (about NT$1.07 million) against an operating loss near NT$278 million and a net loss of NT$265 million, scoring just 9 on the income statement. Cash flow is equally weak at 12, with operating cash burn of roughly NT$248 million and cumulative burn of about NT$1.8 billion since 2020. The balance sheet is the sole relative strength at 56: debt-to-equity of only 0.03 and equity funding roughly 93% of assets means virtually no refinancing risk. However, shareholders' equity has eroded nearly 70% from NT$2.33 billion in 2020 to NT$761 million, implying only about three more years of runway and a likely dilutive capital raise. The constructive note is direction — losses have narrowed roughly 25% since 2020, cash burn is down about 38% from the 2022 peak, and gross margin turned positive at 49% — but there is no commercial engine to support a path to profitability.
Income Statement
9Very NegativeBalance Sheet
56NeutralCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.05M | 1.07M | 1.00M | 1.00M | 1.00M | 550.00K |
| Gross Profit | 443.00K | 520.00K | 477.00K | 552.00K | -6.61M | -5.91M |
| EBITDA | -302.91M | -266.15M | -279.71M | -283.79M | -340.60M | -321.59M |
| Net Income | -296.60M | -264.77M | -293.75M | -296.31M | -349.63M | -329.26M |
Balance Sheet | ||||||
| Total Assets | 679.25M | 819.26M | 1.07B | 1.36B | 1.65B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 636.92M | 771.78M | 1.03B | 1.32B | 1.62B | 2.03B |
| Total Debt | 17.92M | 22.12M | 14.99M | 9.60M | 16.16M | 15.38M |
| Total Liabilities | 62.61M | 58.30M | 38.92M | 46.17M | 40.93M | 92.44M |
| Stockholders Equity | 616.64M | 760.96M | 1.03B | 1.32B | 1.61B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | -257.22M | -248.74M | -296.17M | -291.13M | -400.34M | -300.45M |
| Operating Cash Flow | -256.71M | -248.46M | -294.22M | -286.35M | -399.97M | -300.05M |
| Investing Cash Flow | 4.63M | 5.82M | 6.71M | -5.26M | -590.00K | 149.00K |
| Financing Cash Flow | -9.60M | -9.34M | -8.72M | -8.83M | -19.55M | -34.24M |
Senhwa Biosciences Inc Peers Comparison
Overall Rating
TW:178664Neutral- TW:649241Neutral
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1786 | 64Neutral | TWD 3.89B | 21.40 | ― | 3.67% | -2.25% | -15.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6492 | 41Neutral | TWD 3.44B | -9.07 | ― | ― | 5.00% | -6.49% |
| TW:6875 | 37Underperform | TWD 3.24B | -9.12 | ― | ― | -69.26% | -24.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6492 | Senhwa Biosciences Inc | 30.10 | -13.07 | -30.28% | |
| TW:1786 | SciVision Biotech Inc. | 52.00 | -20.15 | -27.93% | |
| TW:6838 | Formosa Pharmaceuticals, Inc. | 20.60 | -6.85 | -24.95% | |
| TW:6875 | Pharmosa Biopharm Inc. | 25.05 | -24.60 | -49.55% | |
| TW:6885 | BRIM Biotechnology, Inc. | 26.85 | -3.00 | -10.05% | |
| TW:7427 | Great Novel Therapeutics Biotech & Medicals Corp. | 59.50 | 21.41 | 56.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026